• Explore /
  • Poster
  • / Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).

Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Christopher Sweeney

South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia

Christopher Sweeney , Russell Petry , Chang Xu , Ryon Graf , David Fabrizio , Jie He , Ole Gjoerup , Lincoln Pasquina , Zoe June Assaf , Kobe Yuen , Matthew J. Wongchenko , Pratyush Gupta , Sanjeev Mariathasan , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT03016312

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 196)

DOI

10.1200/JCO.2024.42.4_suppl.196

Abstract #

196

Poster Bd #

J4

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.

Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.

First Author: Christopher Sweeney

First Author: Alexander Shiang

First Author: Emmanuel S. Antonarakis

First Author: Justin Shaya